SAUDI ARABIA · PHARMA & BIOPHARMA
Saudi Pharma Localization: When Does It Actually Make Business Sense?
Why European pharmaceutical manufacturers should evaluate localization early — without assuming they should localize.
Saudi Arabia wants more pharmaceutical localization.
That does not mean every pharmaceutical company should localize.
For a European manufacturer, the more important question is not whether localization supports Saudi industrial policy.
It is whether localization improves the business case for the product.
Localization is not the business case. Localization must have a business case.
A national priority is not automatically a corporate priority
Saudi Arabia has established a clear pharmaceutical-localization ambition. The National Industrial Development and Logistics Program targets localization of 40% of the value of the domestic pharmaceutical market, with an emphasis on more advanced products and the development of the Kingdom as a manufacturing base capable of serving regional markets.
Saudi Arabia has strong reasons to pursue localization: supply security, industrial development, technology transfer, employment, advanced manufacturing capabilities and reduced dependence on imported medicines.
A European pharmaceutical manufacturer has a different responsibility. It must determine whether localization creates sufficient value for its product, portfolio and shareholders.
For many products, continued importation may remain the optimal Saudi operating model. If a company can manufacture efficiently in Europe, maintain reliable supply, access the Saudi market successfully and generate attractive returns without additional manufacturing investment, localization should not be pursued simply because it aligns with a national policy objective.
The relevant question is therefore not whether Saudi Arabia wants pharmaceutical localization. That direction is clear.
The more important question is: under what circumstances would localization improve our Saudi business case?
Localization is not a binary decision
Localization is often framed as a choice between importing the product and building a factory. The actual strategic landscape is broader.
A company can commercialize imported products while preserving future manufacturing rights. It can localize selected activities, use contract manufacturing, transfer defined technologies without transferring its entire manufacturing platform, or establish a deeper local manufacturing footprint where the economics and strategic rationale justify it.
The decision is therefore not whether to move from importation to a factory. It is which operating model best fits the business case.
The Optima Localization Options Framework
Rather than viewing localization as a ladder that companies are expected to climb, manufacturers can evaluate four possible operating models.
Preserve the ability to change the operating model as the market develops.
Optionality is not a fifth localization stage. It is a design principle that sits across the entire framework.
Commercial entry and manufacturing localization do not have to happen at the same time
A manufacturer entering Saudi Arabia today may correctly decide to continue importing. Its distribution agreement, commercial structure and partner arrangements do not necessarily need to prevent it from adopting a different operating model later.
This distinction is visible in actual transactions. In February 2026, Avalon Pharma announced an agreement with Bio-Thera for exclusive registration and commercialization rights for a proposed pembrolizumab biosimilar across Saudi Arabia and MENA. Bio-Thera retained development, manufacturing and supply responsibilities, while the agreement gave Avalon additional rights to localize manufacturing in the future.
The transaction does not establish a universal model. It illustrates a strategic principle: a company can develop the market first while preserving the ability to change its operating model later.
Localization can also destroy optionality
Poorly structured localization can create sunk investment, partner dependence, minimum-volume commitments and intellectual-property exposure.
Localization can create optionality — or destroy it. The difference is in the structure.
The question is not simply how to preserve the option to localize. It is also how to localize without unnecessarily surrendering future options.
The best distributor may not be the best localization partner
The best distributor today may not be the best localization partner tomorrow.
Commercial execution, manufacturing, technology transfer and quality systems require different capabilities. Manufacturers should therefore decide deliberately whether these roles belong with one partner or several.
This is why localization architecture should be considered before long-term partner structures unnecessarily narrow the company's choices.
Procurement matters — but it cannot be the assumption
Localization should not be confused with guaranteed procurement success.
Any expected advantage should be tested product by product and procurement pathway by procurement pathway. A localization investment should not depend on an assumed tender benefit that has not been demonstrated.
Advanced pharmaceuticals make the question more immediate
On 16 September 2026, Saudi Arabia's Local Content and Government Procurement Authority announced three agreements covering local production of semaglutide, aflibercept and ustekinumab, including the transfer of knowledge, expertise and advanced technologies. The authority estimated approximately SAR 4.4 billion in GDP contribution and more than 800 jobs from the agreements.
This matters not because every biologics manufacturer should now localize. It matters because localization policy is increasingly translating into specific product-level projects.
For manufacturers operating in biologics, biosimilars and other strategically important technologies, ignoring localization completely until after commercial scale has been achieved may therefore become increasingly difficult to justify.
The CFO Test
Before localization, management should be able to answer five questions:
- What additional volume or strategic value could localization realistically create or protect?
- What capital, operating and technology-transfer costs will it require?
- What happens to COGS, margin and working capital?
- What new partner, quality, regulatory and IP risks are introduced?
- What happens if the expected volume or procurement advantage does not materialize?
If those answers do not support the investment, localization may not yet be the right decision.
The timing problem
Localize too early
The company commits capital, technology and management resources before demand or strategic value has been sufficiently demonstrated. The result may be underutilized capacity, additional complexity and inadequate returns.
Evaluate localization too late
The company enters the market without considering how procurement exposure, partner structure or manufacturing requirements could evolve. Years later, localization may become attractive, but prior commitments may have narrowed the available options.
Make today's market-entry decisions without unnecessarily limiting tomorrow's choices.
A better decision sequence
Validate the Saudi Opportunity
Real addressable demand, not headline market size.
Map Access and Procurement Exposure
Understand where localization could actually matter.
Establish the Imported-Product Economics
The base case must work before localization benefits are assumed.
Model Localization Alternatives
Compare investment, economics, risk and partner requirements.
Preserve Optionality
Commit only when the evidence justifies it.
The Optima Biomed Perspective
Saudi Arabia's pharmaceutical-localization trajectory is clear. But the correct response for a European manufacturer is not automatically to manufacture in Saudi Arabia.
For some manufacturers, the right answer will remain importation.
For others, localization will become commercially compelling.
The strategic advantage lies in knowing why, when and under what conditions the answer should change.
Localization should not begin with a factory decision.
It should begin with a market-entry business case.
Evaluating Saudi Arabia for your pharmaceutical portfolio?
Optima Biomed supports European healthcare companies in evaluating Saudi market-entry models, partner structures, commercialization pathways and localization options before capital and contractual commitments narrow the available choices.